An Open Label Phase II Study of Atezolizumab, Bevacizumab and Memantine in Patients With Hepatocellular Carcinoma
Latest Information Update: 31 Jan 2025
Price :
$35 *
At a glance
- Drugs Atezolizumab (Primary) ; Bevacizumab (Primary) ; Memantine (Primary)
- Indications Liver cancer
- Focus Therapeutic Use
- 31 Jan 2025 New trial record